Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study Followed by a Treatment Extension to Evaluate the Efficacy and Safety of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1

NCT07587021 is registered in ClinicalTrials.gov with YolTech Therapeutics Co., Ltd as lead sponsor.

NCT NCT07587021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07587021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study Followed by a Treatment Extension to Evaluate the Efficacy and Safety of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1
Lead sponsor
YolTech Therapeutics Co., Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
September 16, 2026
Completion date
February 29, 2028
Enrollment
36 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

ph1, primary hyperoxaluria type 1